## 2 Results and Discussion
### Application in Biological Samples
#### 2.4.2 Concentration of Piperacillin and Imipenem in Plasma
\begin{table}
\begin{tabular}{c c c c c c c c c c c} \hline
**Pat.** & **Age** & **Body** & **Microorganisms** & **Other** & **Renal Impairment** & **PCT** & **CRP** & **Albumns** & **Urea** & **Creatinine** \\
**\#** & **[years]** & **Weight** & **[kg]** & **Found** & **Drugs** & **TEnergy** & **[ng/mL]** & **[ng/L]** & **[g/L]** & **[mmol/L]** & **[mmol/L]** \\ \hline \multicolumn{11}{c}{Patients receiving PIPERACILIN} \\ \hline \multirow{3}{*}{1} & \multirow{3}{*}{89} & \multirow{3}{*}{88} & \multicolumn{2}{c}{_P. aeruginosa,_} & \multirow{3}{*}{-} & \multirow{3}{*}{1.27} & \multirow{3}{*}{88.69} & \multirow{3}{*}{34.68} & \multirow{3}{*}{9.4} & \multirow{3}{*}{82.06} \\  & & & & & & & & & & \\  & & & & & & & & & & \\
2 & 28 & 78 & \multicolumn{2}{c}{_P. aeruginosa,_} & \multirow{3}{*}{-} & \multirow{3}{*}{0.13} & \multirow{3}{*}{35.66} & \multirow{3}{*}{33.1} & \multirow{3}{*}{11.6} & \multirow{3}{*}{29.36} \\  & & & & & & & & & & \\  & & & & & & & & & & \\
3 & 60 & 71 & _P. mirabilis, E. coli_ & -} & - & 0.69 & 51.08 & & & & \\  & & & & & & & & & & \\  & & & & & & & & & & \\  & & & & & & & & & & \\
4 & 73 & 64 & - & - & - & 0.45 & 42.08 & 28.99 & & & \\
5 & 83 & 82 & - & - & - & 0.3 & 133.56 & 24.9 & & & \\
6 & 66 & 86 & _P. mirabilis, E. faecalis_ & - & CVVHD & 0.67 & 179.61 & - & 10.3 & & \\
7 & 64 & 88 & _E. coli_ & - & - & 0.19 & 109.19 & 29.89 & & & \\  & & & & & & & & & & \\
8 & 69 & 86 & \multicolumn{2}{c}{spp,_} & \multirow{3}{*}{-} & \multirow{3}{*}{0.06} & \multirow{3}{*}{60.14} & \multirow{3}{*}{31.64} & \multirow{3}{*}{4} & \multirow{3}{*}{28.72} \\
9 & 68 & 68 & _S. hominis_ & - & - & 0.15 & 6.26 & 37.67 & & & \\
10 & 46 & 76 & _K. pneumoniae_ & - & - & 0.28 & 184.35 & 32.86 & & & \\
11 & 77 & 62 & _C. albicans_ & - & - & 2.37 & 195.97 & 28.58 & & & \\ \hline \multicolumn{11}{c}{Patients receiving IMPENEM} \\ \hline \multirow{3}{*}{1} & \multirow{3}{*}{71} & \multirow{3}{*}{83} & \multirow{3}{*}{_E.coli_} & \multirow{3}{*}{piperacillin} & \multirow{3}{*}{4 juresis supported} & \multirow{3}{*}{24.39} & \multirow{3}{*}{105.11} & \multirow{3}{*}{31.73} & \multirow{3}{*}{11} & \multirow{3}{*}{72.62} \\  & & & & & & & & & & \\  & & & & & & & & & & \\  & & & & & & & & & & \\
2 & 57 & 75 & _P. mirabilis_ &piperacillin & CVVHD & 10.04 & 241.85 & & & & \\  & & & & & & & & & & \\  & & & & & & & & & & \\
3 & 77 & 91 & _E.coli, C. albicans_ & - & - & - & 1.21 & 140.11 & - & & \\  & & & & & & & & & & \\  & & & & & & & & & & & \\  & & & & & & & & & & \\
4 & 59 & 84 & _S. aureus_ & - & - & 30.2 & 78.93 & 23.4 & & & \\
5 & 71 & 78 & _S. aureus_ & ceftaxone & CVVHD & 4.72 & 369.99 & 27.64 & & & \\  & & & & & & & & & & \\
6 & 92 & 68 & _K. pneumoniae_ &piperacillin & diuresis supported & 2.64 & 377.4 & & & & & \\  & & & & & & & & & & \\  & & & & & & & & & & & \\  & & & & & & & & & & & \\
7 & 30 & 78 & _Candidia_ spp. & Piperacillin & diuresis supported & 2.36 & 327.57 & 39.73 & & & & \\  & & & & & & & & & & \\  & & & & & & & & & & & \\ \end{tabular}
\end{table} 
Table 6: Characteristics of patients included in blood sampling. Other antibiotics are considered only if administrated within one week before sample collection. PCT—procalcitonin reference range: \(<\)0.05 ng/mL; CRP—Creative protein reference range: \(<\)5 mg/L; Albumins reference range: 32–48 g/L; Urea reference range: 3.2–8.2 mmol/L; Creatinine reference range: 61.9–114.9 \(\mu\)mol/L; CVVHD—continuous veno-venous hemodialysis; FSD—twrosemide.